Pediatric Hematology & Oncology Center

Free consultation

Before you decide where your child is treated, let a pediatric hematologist-oncologist read the file

The review is free and obliges you to nothing. Send the pathology or biopsy report, the bone marrow and imaging reports, and the exact protocol name and phase if treatment has already started, and a pediatric hematologist-oncologist replies in writing with what treatment in Istanbul would involve for your child, and whether traveling is the right step at all.

Childhood cancer is a different disease, treated by a different specialty

Children do not get smaller versions of adult cancers. They get different cancers: acute lymphoblastic leukemia and acute myeloid leukemia in the blood and marrow, Hodgkin and non-Hodgkin lymphoma, and the solid tumors that belong almost entirely to childhood, among them neuroblastoma, Wilms tumor of the kidney, sarcomas of bone and soft tissue, and germ cell tumors. Brain tumors are treated jointly with pediatric neurosurgery.

Most of these diseases run on established international protocols refined over decades of cooperative trials, and cure rates in childhood cancer are, on the whole, higher than in adult oncology. The protocols are demanding. They fix drugs, doses, timing and response checkpoints week by week, sometimes across two years or more, and they are delivered by pediatric hematologist-oncologists and pediatric nurses, because a four-year-old is not a scaled-down adult in any department of a hospital.

At Biruni Hospital the center works inside a university hospital of over 600 beds, with the services a childhood cancer protocol leans on under one roof: pediatric surgery for tumor operations, radiation oncology, pathology, radiology and nuclear medicine imaging for staging and response assessment, and a Pediatric Intensive Care unit, alongside Neonatology, for the rare weeks when a child needs more support than a ward can give.

Some of the children treated here do not have cancer at all. Severe aplastic anemia, where the marrow stops producing blood, demands the same isolation, transfusion support and infection control as leukemia, which is why it belongs in a center built this way. When a transplant is the right treatment, for that disease or for a leukemia that has relapsed, the case moves to the hospital's separate Pediatric Bone Marrow Transplant Center without leaving the building. A small group of B-cell leukemias and lymphomas that have returned after several treatment lines can also be evaluated at the hospital's CAR-T Cell Therapy Center. And for everything in childhood that is not in this territory, the Children's Health and Diseases Center remains the hospital's general pediatric front door.

Why families cross a border for a child's cancer treatment

An estimated 397,000 children develop cancer worldwide each year, and a simulation analysis published in The Lancet Oncology in 2019 concluded that a large share of them are never even diagnosed [1]. Behind that figure sits the fact this whole page rests on. Childhood cancer is, in most cases, a treatable disease, and what separates children who survive from children who do not is less the biology of the tumor than access to complete, uninterrupted treatment.

The same research group modeled five-year survival across the world and found the contrast stark: above 80 percent for children treated in high-income settings, and far lower across much of the globe [2]. The protocols themselves are international and published. What differs from country to country is whether a given child can actually receive every block of one, on schedule, with the supportive care that carries a small body through it.

So a family whose home system cannot deliver the full protocol, or cannot deliver it without interruptions, drug shortages or waiting lists, is not overreacting when it looks abroad. On the published evidence, that family is doing the one thing most likely to change the outcome.

When travel serves your child, and when it wastes days that matter

Suspected acute leukemia sets the hardest deadline in this specialty. A child with abnormal cells in the blood and failing counts should start treatment within days, and the right hospital is the nearest one able to begin. Istanbul can be that hospital when a family can genuinely fly in at once; when it cannot, starting at home and sending the file afterward protects the child better than any journey. No serious center lets a family spend two weeks arranging travel while an acute leukemia advances untreated, and this one does not.

A child already stable on a protocol at home is a different case. Mid-treatment transfer is possible, and families ask for it when trust in the home hospital has broken down, but continuity is itself part of a protocol's strength, so the request is weighed honestly rather than simply accepted. The center asks for the exact protocol name, the current phase and the date the last block ended, weighs what switching would cost against what it would fix, and sometimes replies that finishing where you started is the better medicine. That reply is free, and it is meant.

The cases that travel best are the ones at the beginning. A mass found on an ultrasound, a biopsy still pending, a pathology result the family wants confirmed before months of chemotherapy rest on it: these children lose very little by traveling, because staging and pathology review restart cleanly in Istanbul, and the original slides or blocks can be re-examined here once the first laboratory releases them.

The months of treatment, lived by a whole family

Childhood cancer treatment is counted in months, sometimes in years, and it moves in blocks. Intensive blocks, when chemotherapy runs in cycles and the child is in the hospital or close to it, need the family in Istanbul. Quieter maintenance phases, common in leukemia protocols, can in selected cases continue back home under a written handover that names every drug, every dose and every blood test for the local pediatrician, with agreed thresholds for contacting Istanbul. Whether that split is safe for your child depends on the protocol and on the care available where you live. It is decided case by case, and the expected shape of it is put to you before you commit to anything.

Most families split too. One parent moves to Istanbul with the sick child for the intensive months while the other keeps the household, the job and the siblings going at home, and no page can make that arrangement painless. What can be done is to settle the practical questions early, and three belong to the international office: what long-stay accommodation near the hospital would cost for your dates, whether a parent stays at the child's bedside on the ward, and what schooling, formal or improvised, is possible for a child well enough to study. Ask all three in the first conversation. Airport transfer and help with finding accommodation are arranged through the same office, and an interpreter works beside the family in their own language through consultations and ward rounds.

Each of these questions has a concrete answer, and you should have it in writing before you travel.

After the cure: what the last day of treatment starts

Because most children on complete protocols survive, childhood cancer has a long afterward. A study of adult survivors of childhood cancer published in the New England Journal of Medicine in 2006 found that a majority carried at least one chronic health condition decades after their treatment ended [3]. Cure is the goal here, and it is a realistic one, but a cured child becomes an adult whose medical history matters for life.

Treatment at the center therefore closes with paper the family keeps for decades: a written treatment summary listing every drug with its cumulative dose, every radiation field and every operation, together with a follow-up schedule built on it. Certain chemotherapy drugs call for heart checks at intervals for years afterward. Where a planned treatment could affect growth or later fertility, that conversation happens before treatment begins, while options still exist, and it is raised by the team rather than left for parents to think of. Keep the summary. Your child will need it at twenty-five and at forty-five, in whatever country they then live, and the doctors treating them there will only know what you can show them.

What childhood cancer treatment costs, and why it is priced in phases

Honest pricing in pediatric oncology starts with an admission: no single figure describes a disease treated over one to two years. Aggregator platforms publish numbers anyway, and they are worth reading only as loose context. CureMeAbroad lists pediatric cancer treatment abroad across a range of roughly $3,000 to $40,000 depending on diagnosis and destination, while Bookimed's leukemia listings for Turkey show chemotherapy courses between about $17,000 and $45,000, with induction chemotherapy around $43,000. Those figures skew toward adult treatment, and none of them describes a full pediatric protocol from diagnosis to the end of maintenance.

What actually moves the total is the shape of your child's protocol. Its length in months. How much of it is intensive, with hospital admissions, against how much runs as outpatient maintenance. The imaging and pathology burden of staging and response checks. And the supportive care, transfusions, antibiotics and extra hospital days for complications, which a quoted chemotherapy price rarely includes. Two children with the same diagnosis can generate very different totals for reasons visible only in their files.

For exactly that reason the center does not attach one number to a disease name. After the file review the family receives a written estimate broken into phases, so you can see what the intensive months in Istanbul are expected to cost, what a maintenance handover would change, and where the honest uncertainties lie, before anyone books a flight.

Questions parents ask before deciding

References

1. Ward ZJ, Yeh JM, et al. Estimating the total incidence of global childhood cancer: a simulation-based analysis. The Lancet Oncology. 2019;20(4):483-493.
2. Ward ZJ, Yeh JM, et al. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. The Lancet Oncology. 2019;20(7):972-983.
3. Oeffinger KC, Mertens AC, et al. Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine. 2006;355(15):1572-1582.